{"schema_version":"secwatch.filing_event.v1","accession":"0001517022-26-000019","form_type":"8-K","ticker":"AKBA","cik":"0001517022","company_name":"Akebia Therapeutics, Inc.","filed_at":"2026-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.293254+00:00","generated_at":"2026-05-15T23:32:59.977507+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Akebia Q4 net product revenue $54.3M, full-year 2025 up 49% YoY; Vafseo launch gains traction","bullets":["Q4 total revenue $57.6M (FY2025 $236.2M); net loss narrowed to $12.2M Q4 and $5.3M full year.","Vafseo net product revenue $6.2M Q4, $45.8M full year 2025; 800 prescribers, 91% adherence with observed dosing.","Auryxia net rev $181.5M FY2025; generic competition expected to reduce 2026 Auryxia revenue.","Cash $184.8M vs $51.9M year-end 2024; sufficient for at least two years.","Pipeline: praliciguat Phase 2 FSGS started; AKB-097 basket study in 2H 2026; AKB-9090 Phase 1 in 1H 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001517022-26-000019","json":"https://secwatch.observer/filing/0001517022-26-000019.json","markdown":"https://secwatch.observer/filing/0001517022-26-000019.md","text":"https://secwatch.observer/filing/0001517022-26-000019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1517022/000151702226000019/0001517022-26-000019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1517022/000151702226000019/akba-20260226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:32:59.977507+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}